FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington.	D.C.	20549	

ton, D.C. 20549	OMB APPROVAL

- 1		
	OMB Number:	3235-0287
	Estimated average burden	
	L	0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Name and Address of Reporting Person*     McKinley Kate					2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [ RANI ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) 2051 RINGWOOD AVE					3. Date of Earliest Transaction (Month/Day/Year) 12/16/2023						X	Officer (g below) Ch	ive title ief Busines	Other ( below) S Officer	specify		
(Street) SAN JOSE CA 95131					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person				
(City)	(S	State)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  rivative Securities Acquired, Disposed of, or Beneficially Owned								satisfy the				
1. Title of Security (Instr. 3) 2. Transa Date			Transac			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)			(A) or	5. Amount Securities Beneficially Owned Foll	Fori y (D)	n: Direct   I or Indirect   E nstr. 4)   C	7. Nature of ndirect Beneficial Dwnership				
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
			Table II - De (e.							sed of, convertible			vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amount or Number of Shares		Reported Transaction( (Instr. 4)	3)		
Stock Option (Right to Buy)	\$4.13	12/16/2023		D			250,000	(1)		05/21/2033	Class A Common Stock	250,000	(2)	0	D		
Stock Option (Right to Buy)	\$2.84	12/16/2023		A		250,000		(1)		05/21/2033	Class A Common Stock	250,000	(2)	250,000	D		

## **Explanation of Responses:**

- 1. The shares subject to the option vest as follows: 25% of the shares subject to the option vest on May 22, 2024; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
- 2. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to \$2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.

Kate McKinley

12/19/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.